about
LRP1B deletion is associated with poor outcome for glioblastoma patients.Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasIdiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series.Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors.Etiologic spectrum and prognosis of longitudinally extensive transverse myelopathies.Molecular profiling of gliomas: potential therapeutic implications.Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.Recent developments and controversies in primary central nervous system lymphoma.Emerging circulating biomarkers in glioblastoma: promises and challenges.Presenting signs and symptoms in brain tumors.Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.Brain volumetric analysis and cortical thickness in adults with saccadic intrusions (ocular flutter or opsoclonus-myoclonus syndrome).Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma.P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study.P17.04 Radiomics analysis of primary central nervous system lymphoma (PCNSL) - A LOC network study.Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.[Genetics and brain gliomas].K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway.P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas.P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study.P10.14 Long-term impact of Temozolomide on 1p19q codeleted oligodendrogliomas growth kinetics.Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.Numb chin syndrome as an early symptom of primary and secondary vasculitisMonofocal motor neuropathy with conduction block associated with adalimumab in rheumatoid arthritisVery early electrodiagnostic findings in Guillain-Barré syndromeTranscriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodiesMachine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic OligodendrogliomaGut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretationPretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System LymphomasIntrathecal Trastuzumab as a Potential Cause of Drug-Induced Aseptic Meningitis[Targeted therapy in glioblastoma: update and perspectives]
P50
Q27853220-5159B899-8EBC-40F2-83ED-9D1F81524618Q31150088-0D752093-EF45-4551-9572-92C75BFA47E7Q36196936-242FE7DA-1466-4699-B517-1D17892060F1Q37376639-4FAE3DD8-5A9E-4BEC-AEA4-C1C2EB02D0A0Q37580501-740E044D-19E9-4BBF-A3B6-09DBEE9022CFQ37999071-8DB335FC-5C3B-42B5-B53F-03E2D641C3DBQ38221371-EAA28598-873D-4AA4-B20C-3AFFBA525756Q38539422-F3B59D0F-29AA-47E4-BDA9-81F26C4BE43AQ38557882-314C4565-6576-4D87-8A19-B6B853850239Q38587109-2A6EE9A1-CEB5-4E77-B884-950E72D0D707Q38591062-70130F82-780A-4AFB-BDB9-0E0D4106D7C5Q38762962-AB4A0790-126A-4D5D-99D4-73519E01BC75Q39612508-44F5211D-8DC9-4BF5-84F0-BFFE05D691E7Q47977516-EA54C082-33A0-4D93-8877-B2D95FCD7502Q48295109-E8F53D71-9CC8-4DAF-9A05-EBCE3F5E757BQ50043854-B4C7091A-8B19-47AE-88A3-91B8F2348408Q50061613-FB6AD563-F796-44AA-921B-4FB20A855E76Q50335799-0ABC40D6-A56B-47BC-BAB6-1473B3219508Q50352759-A733AD5B-EFFE-403B-B173-F3A95EF6D086Q50537515-FCBC18B8-6F1D-4290-8D1F-DA93C48AB4C2Q52145873-88DCAAF3-AA0D-48D4-82BF-77782B90070EQ52627424-5BE4C825-BB5D-4934-8CF9-604BDAD55DEBQ53201539-A069EB51-9A33-4077-8532-35FB67351DB0Q54971929-4A5A1B48-4EBE-46EC-9D75-E5B0AD139EE0Q55123970-EDA6E77A-4B47-4ABD-9992-C1493894D6CCQ55167554-8F597213-4D6B-4A59-9065-39F5BDFBA92DQ55459936-07363EA7-E965-47BC-8760-27D63F6BB2E2Q84059544-77168B51-D81C-4AEA-B108-3FA59158689CQ84379303-8F45264A-7CF6-4ECB-9C36-765D80C3BED0Q84408900-FAF83520-A5A1-439E-A1F7-221D9327911CQ89094817-57575DE8-05CD-49F9-9C8B-4F440C51A8A8Q90292717-21D13C34-292E-4FD0-94C2-F806A7C82246Q92270895-91EAA65E-8DFB-42D3-8FE0-55CA880E1BA1Q92339678-5181357A-E01D-45B7-AF5F-F09B6E49034FQ92578166-193B0F49-4390-4A7B-964A-000B4A99CFC0Q95576930-AC062097-C261-4EBB-9CE2-7116AEED43E6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
A Alentorn
@ast
A Alentorn
@en
A Alentorn
@es
A Alentorn
@nl
type
label
A Alentorn
@ast
A Alentorn
@en
A Alentorn
@es
A Alentorn
@nl
prefLabel
A Alentorn
@ast
A Alentorn
@en
A Alentorn
@es
A Alentorn
@nl
P106
P31
P496
0000-0002-7220-2686